Dr Reddy's may spend $400 million on R&D in 4 years

Dr Reddy's Laboratories may invest up to $400 million on R&D over 3-4 years in biologics and proprietary products where it sees a wave of big growth going forward.

"The R&D investments are likely to increase over the coming years. DRL may cumulatively invest in biologics in the range of $150 million to $200 million and proprietary products in the range of $150 to 200 million over next 3 to 4 years till these respective businesses become self- sufficient and cash accretive," said a company source.

DRL had 21 active products in the proprietary products pipeline, of which six were in clinical development stage as on March 31, 2013, as per a filing with the US Food and Drug Administration last year.

The company had said that drugs currently in clinical development stage are targeted in the areas of cardiovascular disorders, psoriasis, pain, anti-infective atopic dermatitis/ psoriasis and migraine.

It said the new drug research on metabolic disorders/ cardiovascular disorders is in Phase-II while the remaining five drugs are in the clinical stage.

DRL vice chairman and managing director K Satish Reddy, without putting a number, said the future R&D focus of the company would be in biologics and proprietary products and expects them to add significant portion of company revenues after five years.

"The bigger investments in R&D are going in to biologics and proprietary products, which is the next big wave. So this will start adding significant portion of our revenues five years hence," Reddy told PTI.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Those willfully defaulting on loans should be blacklisted by Sebi

    As reported by this newspaper’s Monday edition, the Securities and Exchange Board of India (Sebi) has found merit in the Reserve Bank of India’s s

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Kumar Jain

Kickstarting technological innovation

One of the key dimensions of global competitiveness is the ...

Kuruvilla Pandikattu SJ

Developing moral, spiritual capacity

Writing in The Huffington Post, Noam Chomsky, professor emeritus, MIT ...

Gautam Gupta

Manufacturing must keep workers’ welfare in mind

It may be early days yet, but the labour reforms ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture